EpiCept to Report Fourth Quarter and Full-Year 2007 Operating and Financial Results on February 29, 2008

EpiCept to Report Fourth Quarter and Full-Year 2007 Operating and Financial
Results on February 29, 2008

    TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 26, 2008--Regulatory News:

    EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it will host a conference call to discuss fourth
quarter and full-year 2007 operating and financial results on Friday,
February 29, 2008 at 9:00 a.m. Eastern time. The call will follow the
release of these financial results earlier in the day at 12:01 a.m.
Eastern time.

    To participate in the live call, please dial (888) 802-7346 from
the U.S. or Canada or (973) 582-2785 from international locations
(please reference access code 37237578). The conference call will also
be broadcast live on the Internet and may be accessed at
www.epicept.com. The web cast will be archived for 90 days.

    A telephone replay of the call will be available for seven days by
dialing (800) 642-1687 from the U.S. and Canada or (706) 645-9291 from
international locations (please reference reservation number
37237578).

    About EpiCept Corporation

    EpiCept is focused on unmet needs in the treatment of pain and
cancer. The Company's broad portfolio of pharmaceutical product
candidates includes several pain therapies in clinical development and
a lead oncology compound for AML with demonstrated efficacy in a Phase
III trial; a marketing authorization application for this compound is
approaching a decision in Europe. In addition, EpiCept's ASAP
technology, a proprietary live cell high-throughput caspase-3
screening technology, can efficiently identify new cancer drug
candidates and molecular targets that selectively induce apoptosis in
cancer cells. Two oncology drug candidates currently in clinical
development that were discovered using this technology have also been
shown to act as vascular disruption agents in a variety of solid
tumors.

    Forward-Looking Statements

    This news release and any oral statements made with respect to the
information contained in this news release, contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals,
targets, future development and are otherwise not statements of
historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by
such forward-looking statements. Factors that may cause actual results
or developments to differ materially include: the risk that Ceplene
will not receive regulatory approval or marketing authorization in the
EU or that if approved it will not achieve significant commercial
success, the risks associated with our need to raise additional
financing to continue to meet our capital needs and our ability to
continue as a going concern, the risk that Myriad's development of
Azixa will not be successful, the risk that Azixa(TM) will not receive
regulatory approval or achieve significant commercial success, the
risk that we will not receive any significant payments under our
agreement with Myriad, the risk that the development of our other
apoptosis product candidates will not be successful, the risk that our
ASAP technology will not yield any successful product candidates, the
risk that clinical trials for NP-1 or EPC 2407 will not be successful,
that NP-1 or EPC 2407 will not receive regulatory approval or achieve
significant commercial success, the risk that our other product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later stage clinical trials, the risk that EpiCept will not obtain
approval to market any of its product candidates, the risks associated
with dependence upon key personnel, the risks associated with reliance
on collaborative partners and others for further clinical trials,
development, manufacturing and commercialization of our product
candidates; the cost, delays and uncertainties associated with our
scientific research, product development, clinical trials and
regulatory approval process; our history of operating losses since our
inception; competition; litigation; risks associated with prior
material weaknesses in our internal controls; and risks associated
with our ability to protect our intellectual property. These factors
and other material risks are more fully discussed in EpiCept's
periodic reports, including its reports on Forms 8-K, 10-Q and 10-K
and other filings with the U.S. Securities and Exchange Commission.
You are urged to carefully review and consider the disclosures found
in EpiCept's filings which are available at www.sec.gov or at
www.epicept.com. You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be wrong
due to inaccurate assumptions, unknown risks or uncertainties or other
risk factors.

    EPCT-GEN

    *Azixa is a registered trademark of Myriad Genetics, Inc.


    CONTACT: EpiCept Corporation:
             Robert W. Cook, 914-606-3500
             rcook@epicept.com
             or
             Media:
             Feinstein Kean Healthcare
             Greg Kelley, 617-577-8110
             gregory.kelley@fkhealth.co
             or
             Investors:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             or
             Bruce Voss, 310-691-7100   bvoss@lhai.com